EICHOR

Recruiting studies: Nasopharyngeal Cancer Recurrent

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
Phase 2 · 2 location(s) · Sun Yat-sen University · NCT07325539 Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT04136886 Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objective
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT01365169 A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance
Phase 2 · 15 location(s) · Shanghai Henlius Biotech · NCT06839066 Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT06669611 Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma
Phase 2 · 1 location(s) · Ming-Yuan Chen · NCT07581821 A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 3 · 1 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT06629597 A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasophary
Phase 4 · 13 location(s) · Coherus Oncology, Inc. · NCT06457503 A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemothera
Phase 2/Phase 3 · 1 location(s) · Sun Yat-sen University · NCT06241599 TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous
Phase 1 · 2 location(s) · Emory University · NCT06868433 Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT05877872 Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
Phase 3 · 6 location(s) · Sun Yat-sen University · NCT04453813 Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT05854849 A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Me
Phase 3 · 1 location(s) · Shanghai Miracogen Inc. · NCT06976190 Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07101744 Proton Therapy for Recurrent Nasopharyngeal Carcinoma
NA · 2 location(s) · Guangzhou Concord Cancer Center · NCT07412314 Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
Phase 2 · 2 location(s) · Shanghai Institute Of Biological Products · NCT06194656 Deep Learning-based sbORN Diagnostic Model
Phase N/A · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06463392 Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06509009 Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carc
Phase 2 · 1 location(s) · Jiangxi Provincial Cancer Hospital · NCT07277764 Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasophary
Phase 2 · 4 location(s) · Sun Yat-sen University · NCT07528183 SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06323239 Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Tr
Phase 2 · 6 location(s) · Ming-Yuan Chen · NCT07070479 Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone i
Phase 2 · 6 location(s) · National Cancer Institute (NCI) · NCT06980038 Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic
Phase 1 · 1 location(s) · Sun Yat-sen University · NCT07584499 Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC
Phase 2 · 1 location(s) · Ming-Yuan Chen · NCT06472713 Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients
NA · 1 location(s) · Affiliated Hospital of Nantong University · NCT06389201 TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06912711 Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Meta
Phase 2 · 88 location(s) · National Cancer Institute (NCI) · NCT06029270 Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
Phase 3 · 12 location(s) · Sun Yat-sen University · NCT05340491

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →